- Home
- AKA vs INBX Comparison
AKA vs INBX Comparison
Compare AKA & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKA
- INBX
- Stock Information
- Founded
- AKA 2018
- INBX 2010
- Country
- AKA United States
- INBX United States
- Employees
- AKA N/A
- INBX N/A
- Industry
- AKA Catalog/Specialty Distribution
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- AKA Consumer Discretionary
- INBX Health Care
- Exchange
- AKA Nasdaq
- INBX Nasdaq
- Market Cap
- AKA 251.5M
- INBX 237.5M
- IPO Year
- AKA 2021
- INBX 2020
- Fundamental
- Price
- AKA $23.20
- INBX $15.64
- Analyst Decision
- AKA Buy
- INBX Hold
- Analyst Count
- AKA 4
- INBX 1
- Target Price
- AKA $18.75
- INBX N/A
- AVG Volume (30 Days)
- AKA 9.9K
- INBX 115.8K
- Earning Date
- AKA 11-06-2024
- INBX 08-13-2024
- Dividend Yield
- AKA N/A
- INBX N/A
- EPS Growth
- AKA N/A
- INBX N/A
- EPS
- AKA N/A
- INBX 118.83
- Revenue
- AKA $555,516,000.00
- INBX $1,687,000.00
- Revenue This Year
- AKA $4.07
- INBX N/A
- Revenue Next Year
- AKA $3.86
- INBX N/A
- P/E Ratio
- AKA N/A
- INBX $0.13
- Revenue Growth
- AKA N/A
- INBX 24.26
- 52 Week Low
- AKA $5.01
- INBX $10.80
- 52 Week High
- AKA $33.73
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- AKA 52.84
- INBX 52.98
- Support Level
- AKA $17.20
- INBX $14.67
- Resistance Level
- AKA $24.40
- INBX $16.35
- Average True Range (ATR)
- AKA 1.90
- INBX 0.58
- MACD
- AKA -0.10
- INBX -0.08
- Stochastic Oscillator
- AKA 65.43
- INBX 57.74
About AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.